
Surrozen (SRZN) Stock Forecast & Price Target
Surrozen (SRZN) Analyst Ratings
Bulls say
Surrozen is viewed favorably because its lead asset SZN-8141 combines Wnt agonism with anti-VEGF activity, aiming to address the durability and efficacy gaps seen with current retinal therapies in DME and potentially other retinal diseases. The thesis is strengthened by Merck’s positive BRUNELLO results, which validate Wnt biology in the retina, while Surrozen’s expanded Phase 2a DUET study from n=60 to n=150 and inclusion of both treatment-naive and treatment-experienced patients should improve dose selection and create a more robust clinical dataset. With first DME patients dosed, topline Phase Ib data still expected in 2H27, Phase IIa results guided for 2028, and an anticipated YE27 net cash position supporting development, the company has multiple value-driving catalysts ahead.
Bears say
Surrozen is a clinical-stage biotech facing elevated fundamental risk because its lead retinal assets, including SZN-8141 and SZN-8143, still have unproven clinical benefit while delays in IND-enabling studies, unexpected toxicity, or broader development setbacks could derail progress. The investment case is further weakened by the failure of the Phase Ib/IIa DUET study in DME and the possibility that Merck’s Restoret Phase IIb/III study could fail, which would hurt confidence in the Wnt agonist class in retinal disease. With the retinal disease market described as extremely competitive and Surrozen needing substantial financing for development and commercialization, any inability to raise capital on favorable terms could pressure the stock.
This aggregate rating is based on analysts' research of Surrozen and is not a guaranteed prediction by Public.com or investment advice.
Surrozen (SRZN) Analyst Forecast & Price Prediction
Start investing in Surrozen (SRZN)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Surrozen (SRZN) Forecast
Surrozen (SRZN) Analyst Forecast & Price Prediction
Start investing in Surrozen (SRZN)
Order type
Buy in
Order amount
Est. shares
0 shares